# OnCo record forty-seven (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/forty-seven/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "forty-seven" ;
  schema:name "Forty Seven"@en ;
  schema:alternateName "Forty Seven, Inc."@en, "NASDAQ:FTSV"@en ;
  schema:description "Forty Seven developed magrolimab, an antibody that blocks CD47, a signal cancer cells use to stop immune cells from swallowing them. Gilead bought the company in 2020."@en ;
  schema:url <https://onco.cc/companies/forty-seven/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/1667633/000119312520057799/d890968dex991.htm>, <https://www.sec.gov/Archives/edgar/data/1667633/000110465920043980/a20-14980_68k.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/cd47/> ;
  onco:drugs <https://onco.cc/drugs/magrolimab/> .